Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03286842 · ClinicalTrials.gov registry record · Phase 3
To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
A Phase 3 study of HER2-ve Metastatic Breast Cancer and Germline BRCA1/2 Mutations, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 256
- Enrollment target
- 20
- Study locations
NCT03286842 is a Phase 3 study of HER2-ve Metastatic Breast Cancer and Germline BRCA1/2 Mutations that has completed, run by AstraZeneca. The registered enrollment target is 256 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT03286842, a Phase 3 study of HER2-ve Metastatic Breast Cancer and Germline BRCA1/2 Mutations, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 256 participants
- Enrollment target
- 20
- Study locations
Study Summary
This open-label, multi-centre phase IIIb study will assess the effectiveness, benefits and potential harms in the use of olaparib monotherapy treatment for patients with HER2-ve metastatic breast cancer associated with germline or somatic breast cancer susceptibility gene (gBRCA1/2 or sBRCA1/2) mutations.
Conditions Studied
Interventions
- DRUG Olaparib
Study Locations (20)
Other
- Research Site - Plovdiv
- Research Site - Sofia
- Research Site - Sofia
- Research Site - Varna
- Research Site - Angers
- Research Site - Avignon
- Research Site - Besançon
- Research Site - Bordeaux
- Research Site - Caen
- Research Site - Le Mans
- Research Site - Lille
- Research Site - Limoges
- Research Site - Lorient
- Research Site - Marseille
- Research Site - Montpellier
Maryland
- Research Site - Towson
Mississippi
- Research Site - Jackson
British Columbia
- Research Site - Vancouver
Ontario
- Research Site - Toronto
Quebec
- Research Site - Québec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2018-01-17 |
| Est. Completion | 2021-10-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03286842
The ClinicalTrials.gov registry entry for NCT03286842 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with HER2-ve Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Olaparib is the first listed.
NCT03286842 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Maryland, Mississippi.
Frequently Asked Questions
What is clinical trial NCT03286842 about?
NCT03286842 is a clinical study titled "To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.". This open-label, multi-centre phase IIIb study will assess the effectiveness, benefits and potential harms in the use of olaparib monotherapy treatment for patients with HER2-ve metastatic breast cancer associated with germline or somatic breast cancer susceptibility gene (gBRCA1/2 or sBRCA1/2) muta...
What is the current status of trial NCT03286842?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 256 participants. The study started on 2018-01-17. Estimated completion is 2021-10-08.
What conditions does trial NCT03286842 study?
This clinical trial studies the following conditions: HER2-ve Metastatic Breast Cancer, Germline BRCA1/2 Mutations, Somatic BRCA1/2 Mutations.
What interventions are being tested in trial NCT03286842?
The interventions under investigation include: Olaparib (DRUG).
Who is sponsoring clinical trial NCT03286842?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03286842 being conducted?
This trial has 20 study locations across Maryland, Mississippi, British Columbia, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.